Clinical Trial Update: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating a multi-agent combination including thalidomide, lenalidomide, carfilzomib, bortezomib, and vorinostat as initial the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)
• Revlimid (lenalidomide)
• Thalidomide (thalidomide)
• Velcade (bortezomib)
• Zolinza (vorinostat)

Snippet

Sponsor: University of Leeds | Conditions: Multiple Myeloma | Phase 3 | Status: UNKNOWN